Shareholders of Virinchi Limited have approved the acquisition of its primary and secondary healthcare business division operating under the Bristlecone Hospitals brand. The transaction involves a slump sale from Virinchi Health Care Private Limited, identified as a material subsidiary of the company. This consolidation moves key healthcare assets into the parent entity’s direct control, streamlining operations for this significant segment of the group.

The resolution was passed through a postal ballot process that concluded on August 10, 2026. The voting exercise was conducted in compliance with Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Section 108 and 109 of the Companies Act, 2013. CS Vinay Babu Gade served as the independent scrutinizer for the voting process, ensuring adherence to regulatory guidelines including relevant MCA circulars.

Voting Results Breakdown

The approval reflects strong shareholder confidence in the restructuring move. Out of 37,924 shareholders on the record date of July 3, 2026, participation was driven primarily by public non-institutional investors. Promoters and institutional investors did not cast votes in this ballot.

The total number of valid votes cast was 5,510,829. There were no invalid votes recorded during the e-voting period, which ran from July 12, 2026, to August 10, 2026. Central Depository Services (India) Limited (CDSL) facilitated the remote e-voting facility.

Transaction Details

The acquisition is structured as a slump sale, allowing for the transfer of the entire business division as a going concern rather than asset-by-asset. This approach typically simplifies the legal and operational transition of staff, contracts, and liabilities associated with the Bristlecone Hospitals brand. The promoters of Virinchi Limited are interested parties in this resolution, as noted in the filing disclosures.

What the Numbers Show

The high level of support—over 95%—from public non-institutional shareholders indicates broad alignment with the company’s strategy to consolidate its healthcare assets. Notably, the promoter group, holding 44,475,538 shares, abstained from voting. This abstention is common in related-party transactions where promoters may recuse themselves to ensure independent shareholder validation, thereby strengthening the governance credibility of the approval.

Virinchi Ltd has revised its audited financial results for the quarter and year ended March 31, 2026, following the identification of discrepancies in its earlier filing. The company submitted the revised XBRL documents to the National Stock Exchange of India on June 29, 2026, to correct specific data points across its standalone and consolidated reports. The restatement addresses errors in earnings per share (EPS) figures, segment reporting details, and profit after tax (PAT) numbers to ensure accuracy and compliance with regulatory standards.

The corrections were necessitated by four primary mistakes identified in the original submission. The standalone report contained incorrect EPS figures for discontinued operations, which were erroneously listed despite the absence of profits from such operations. Additionally, there was a mismatch in the segment details provided in the standalone XBRL file compared to the PDF version of the report. On the consolidated front, the company rectified discrepancies in both the PAT figures and the yearly EPS figures that differed between the XBRL and PDF formats.

Key Corrections Made

The filing outlined the specific areas where the data was rectified to align the XBRL submission with the audited financial statements.

The submission was communicated by K Ravindranath Tagore, Company Secretary of Virinchi Limited, confirming that the revised files have been uploaded for the exchange's information and records.